{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:00:16Z","timestamp":1792476016793,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Professional society practice guidelines conflict regarding their recommendations of dofetilide (DOF) and sotalol (STL) for treatment of arrhythmias in hypertrophic cardiomyopathy (HCM), and supporting data is sparse. We aim to assess safety and efficacy of DOF and STL on arrhythmias in HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational study of HCM patients treated with DOF or STL for atrial fibrillation (AF) and ventricular arrhythmias (VA). Outcomes of drug discontinuation and arrhythmia recurrence were compared at 1 year and latest follow-up by Kaplan\u2013Meier analysis. Predictors of drug failure were studied using uni- and multi-variable analyses. Drug-related adverse events were quantitated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show that of our cohort of 72 patients (54\u2009\u00b1\u200914 years old, 75% male), 21 were prescribed DOF for AF, 52 STL for AF, and 18 STL for VA. At 1 year, discontinuation and recurrence rates were similar for DOF-AF (38% and 43%) and STL-AF (29% and 44%) groups. Efficacy data was similar at long-term follow-up of 1603 (IQR 994\u20134131) days, and for STL-VA. Drug inefficacy was the most common reason for discontinuation (28%) followed by side-effects (13%). Incidences of heart failure hospitalization (5%) and mortality (3%) were low. One STL-AF patient developed non-sustained torsades de pointes in the setting of severe pneumonia and acute kidney injury, but there were no other drug-related serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DOF and STL demonstrate modest efficacy and satisfactory safety when used for AF and VA in HCM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-023-00315-8","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:02:12Z","timestamp":1689757332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-2051","authenticated-orcid":false,"given":"Chris","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwoo","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Stecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Nazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"315_CR1","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2021.03.008","volume":"77","author":"H Cui","year":"2021","unstructured":"Cui, H. et al. Myocardial histopathology in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 77, 2159\u20132170 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto, I. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104, 2517\u20132524 (2001).","journal-title":"Circulation"},{"key":"315_CR3","doi-asserted-by":"publisher","first-page":"L11","DOI":"10.1093\/eurheartj\/suaa125","volume":"22","author":"C Autore","year":"2020","unstructured":"Autore, C. & Musumeci, M. B. The natural history of hypertrophic cardiomyopathy. Eur. Heart J. Suppl. J. Eur. Soc. Cardiol. 22, L11\u2013L14 (2020).","journal-title":"Eur. Heart J. Suppl. J. Eur. Soc. Cardiol."},{"key":"315_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.65.7.1388","volume":"65","author":"BJ Maron","year":"1982","unstructured":"Maron, B. J., Roberts, W. C. & Epstein, S. E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 65, 1388\u20131394 (1982).","journal-title":"Circulation"},{"key":"315_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM200002103420601","volume":"342","author":"BJ Maron","year":"2000","unstructured":"Maron, B. J. et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342, 365\u2013373 (2000).","journal-title":"N. Engl. J. Med."},{"key":"315_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1253\/circj.CJ-09-0140","volume":"73","author":"T Kubo","year":"2009","unstructured":"Kubo, T. et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ. J. 73, 1599\u20131605 (2009).","journal-title":"Circ. J."},{"key":"315_CR7","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","volume":"124","author":"BJ Gersh","year":"2011","unstructured":"Gersh, B. J. et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 124, 2761\u20132796 (2011).","journal-title":"Circulation"},{"key":"315_CR8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January, C. T. et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, 2071\u20132104 (2014).","journal-title":"Circulation"},{"key":"315_CR9","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January, C. T. et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 140, e125\u2013e151 (2019).","journal-title":"Circulation"},{"key":"315_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid, M. V. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 45, 1251\u20131258 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/pace.12426","volume":"37","author":"R Chung","year":"2014","unstructured":"Chung, R. et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin. Electrophysiol. PACE. 37, 1338\u20131348 (2014).","journal-title":"Pacing Clin. Electrophysiol. PACE."},{"key":"315_CR12","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 76, 3022\u20133055 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron, B. J. et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 390\u2013414 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/pace.13310","volume":"41","author":"JC Moore","year":"2018","unstructured":"Moore, J. C. et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review. Pacing Clin. Electrophysiol. PACE 41, 396\u2013401 (2018).","journal-title":"Pacing Clin. Electrophysiol. PACE"},{"key":"315_CR15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","volume":"123","author":"CAS Miller","year":"2019","unstructured":"Miller, C. A. S. et al. Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy. Am. J. Cardiol. 123, 1859\u20131862 (2019).","journal-title":"Am. J. Cardiol."},{"key":"315_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0002-9149(84)80212-X","volume":"54","author":"WJ McKenna","year":"1984","unstructured":"McKenna, W. J. et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 54, 802\u2013810 (1984).","journal-title":"Am. J. Cardiol."},{"key":"315_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/hrt.53.4.412","volume":"53","author":"WJ McKenna","year":"1985","unstructured":"McKenna, W. J., Oakley, C. M., Krikler, D. M. & Goodwin, J. F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart J. 53, 412\u2013416 (1985).","journal-title":"Br. Heart J."},{"key":"315_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","volume":"42","author":"L Monserrat","year":"2003","unstructured":"Monserrat, L. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 42, 873\u2013879 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR19","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.hrthm.2015.03.042","volume":"12","author":"M Bassiouny","year":"2015","unstructured":"Bassiouny, M. et al. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm. 12, 1438\u20131447 (2015).","journal-title":"Heart Rhythm."},{"key":"315_CR20","first-page":"1409","volume":"23","author":"A Creta","year":"2021","unstructured":"Creta, A. et al. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study. EP Eur. 23, 1409\u20131417 (2021).","journal-title":"EP Eur."},{"key":"315_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/europace\/euv339","volume":"18","author":"DS Zhao","year":"2016","unstructured":"Zhao, D. S. et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace 18, 508\u2013520 (2016).","journal-title":"Europace"},{"key":"315_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","volume":"15","author":"K Robinson","year":"1990","unstructured":"Robinson, K. et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. 15, 1279\u20131285 (1990).","journal-title":"J. Am. Coll. Cardiol."},{"key":"315_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2020.07.036","volume":"318","author":"M Ciabatti","year":"2020","unstructured":"Ciabatti, M. et al. Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 318, 94\u2013100 (2020).","journal-title":"Int. J. Cardiol."},{"key":"315_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron, M. S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295\u2013303 (2003).","journal-title":"N. Engl. J. Med."},{"key":"315_CR25","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","volume":"27","author":"PM Elliott","year":"2006","unstructured":"Elliott, P. M. et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur. Heart J. 27, 1933\u20131941 (2006).","journal-title":"Eur. Heart J."},{"key":"315_CR26","doi-asserted-by":"crossref","unstructured":"Lu, D. et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J. Am. Heart Assoc. 7, e006657 (2018).","DOI":"10.1161\/JAHA.117.006657"},{"key":"315_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/01.CIR.66.5.1087","volume":"66","author":"C Pollick","year":"1982","unstructured":"Pollick, C., Morgan, C. D., Gilbert, B. W., Rakowski, H. & Wigle, E. D. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 66, 1087\u20131094 (1982).","journal-title":"Circulation"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00315-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T09:35:28Z","timestamp":1689759328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00315-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1038\/s43856-023-00315-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2391095\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}